Ad is loading...
HWSCX
Price
$63.01
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
VISVX
Price
$50.61
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

HWSCX vs VISVX

Header iconHWSCX vs VISVX Comparison
Open Charts HWSCX vs VISVXBanner chart's image
Hotchkis & Wiley Small Cap Value C
Price$63.01
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Vanguard Small Cap Value Index I
Price$50.61
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
HWSCX vs VISVX Comparison Chart
Loading...
View a ticker or compare two or three
VS
HWSCX vs. VISVX commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HWSCX is a Buy and VISVX is a Buy.

FUNDAMENTALS
Fundamentals
VISVX has more cash in the bank: 57.6B vs. HWSCX (854M). VISVX pays higher dividends than HWSCX: VISVX (1.90) vs HWSCX (0.41). HWSCX was incepted earlier than VISVX: HWSCX (23 years) vs VISVX (27 years). HWSCX is a more actively managed with annual turnover of: 42.00 vs. VISVX (16.00). HWSCX has a lower initial minimum investment than VISVX: HWSCX (2500) vs VISVX (3000). VISVX annual gain was more profitable for investors over the last year : 30.04 vs. HWSCX (18.33). VISVX return over 5 years is better than : 62.14 vs. HWSCX (47.30).
HWSCXVISVXHWSCX / VISVX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence23 years27 years-
Gain YTD9.29717.71252%
Front LoadN/AN/A-
Min. Initial Investment2500300083%
Min. Initial Investment IRAN/AN/A-
Net Assets854M57.6B1%
Annual Yield % from dividends0.411.9022%
Returns for 1 year18.3330.0461%
Returns for 3 years8.8716.9252%
Returns for 5 years47.3062.1476%
Returns for 10 years7.41109.837%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EFXT9.240.20
+2.21%
Enerflex Ltd
RVSN0.440.01
+1.60%
Rail Vision Ltd
CAG27.170.05
+0.18%
Conagra Brands
FULC2.97-0.02
-0.67%
Fulcrum Therapeutics
KYMR43.51-0.54
-1.23%
Kymera Therapeutics